5/23
05:20 pm
imab
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 [Yahoo! Finance]
Low
Report
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 [Yahoo! Finance]
5/23
05:05 pm
imab
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
Low
Report
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024
5/22
07:00 am
imab
I-Mab to Participate at the Jefferies Global Healthcare Conference
Low
Report
I-Mab to Participate at the Jefferies Global Healthcare Conference
4/30
07:10 am
imab
I-MAB Filed 2023 Annual Report on Form 20-F [Yahoo! Finance]
Low
Report
I-MAB Filed 2023 Annual Report on Form 20-F [Yahoo! Finance]
4/30
07:00 am
imab
I-MAB Filed 2023 Annual Report on Form 20-F
Low
Report
I-MAB Filed 2023 Annual Report on Form 20-F
4/12
08:01 am
imab
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Low
Report
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
4/5
07:14 am
imab
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/5
07:00 am
imab
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
4/2
04:04 pm
imab
I-Mab Announces Closing of the Divestiture of Business Operations in China [Yahoo! Finance]
Low
Report
I-Mab Announces Closing of the Divestiture of Business Operations in China [Yahoo! Finance]
4/2
04:01 pm
imab
I-Mab Announces Closing of the Divestiture of Business Operations in China
Low
Report
I-Mab Announces Closing of the Divestiture of Business Operations in China
3/18
02:53 pm
imab
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock, down previously from $18.00.
Low
Report
I-Mab (NASDAQ: IMAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock, down previously from $18.00.
3/18
02:52 pm
imab
I-Mab (NASDAQ: IMAB) had its price target lowered by analysts at Piper Sandler from $15.00 to $10.00. They now have an "overweight" rating on the stock.
Low
Report
I-Mab (NASDAQ: IMAB) had its price target lowered by analysts at Piper Sandler from $15.00 to $10.00. They now have an "overweight" rating on the stock.
3/18
07:02 am
imab
I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
3/14
05:09 pm
imab
I-Mab Reports Full Year 2023 Financial Results and Business Update [Yahoo! Finance]
Medium
Report
I-Mab Reports Full Year 2023 Financial Results and Business Update [Yahoo! Finance]
3/14
05:00 pm
imab
I-Mab Reports Full Year 2023 Financial Results and Business Update
Medium
Report
I-Mab Reports Full Year 2023 Financial Results and Business Update